CLINICAL TRIAL: P3 PACLITAXEL +BEVACIZUMB AS 1ST-LINE THER -LOCALLY RECURROR MET

临床试验：P3 紫杉醇贝伐珠单抗作为第一线局部复发治疗药物

• 批准号: 7951359
• 负责人: Witold B. Rybka
• 金额: $ 0.32万
• 依托单位: PENNSYLVANIA STATE UNIV HERSHEY MED CTR
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-01 至 2010-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7951359
• 关键词: Clinical Research; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Institution; Paclitaxel; Patients; Research; Research Personnel; Resources; Source; United States National Institutes of Health; bevacizumab; malignant breast neoplasm; meetings

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this research is to compare the effects of paclitaxel in combination with bevacizumab or paclitaxel alone in patients with breast cancer that has spread or reocurred.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 本研究的目的是比较紫杉醇联合贝伐单抗或单用紫杉醇对已扩散或复发的乳腺癌患者的疗效。